Context: T helper (Th)17 cells are correlated with many human autoimmune disorders, including Graves disease, and may play key roles in the pathogenesis of Graves orbitopathy (GO).
A lthough the role of autoimmunity is somehow delineated in Graves disease, its role in Graves orbitopathy (GO) is incompletely defined (1, 2) . The orbital fibroblasts (OFs) interact with autologous lymphocytes and promote the production of copious cytokines and extracellular matrix (ECM), which further contribute to severe orbital inflammation (1) (2) (3) .
Fibrosis and adipogenesis are the two major pathological changes of GO (3, 4) . As the target cells in the development of GO, the OF heterogeneity determines the outcome of orbital tissue remodeling and clinical manifestation. The cell surface marker CD90 divides OFs into two subpopulations that exhibit phenotypic and functional heterogeneity. The CD90 + OFs favors fibrosis whereas the CD90 2 OFs tend to cause adipose hyperplasia (3) (4) (5) . T helper (Th)17 cells are involved in immunopathology and autoinflammatory diseases such as psoriasis, rheumatoid arthritis, Crohn disease, and multiple sclerosis (6, 7) . Recent researches indicate that interferon (IFN)-g and interleukin (IL)-22-expressing Th17 cells are pathogenic and able to drive inflammatory responses (8, 9) . Our previous studies showed an increased level of IL-17A-producing T cells in GO patients and IL-17A could evoke inflammatory responses as well as induce fibrosis in the orbits (10, 11) . However, it remains unclear about whether these elevated Th17 cells in patients with GO have pathogenic phenotypes. Furthermore, the putative involvement of the IL-17A pathways in regulating the balance between fibrosis and adipogenesis in GO has yet to be examined carefully.
In the present study, we report increased pathogenic Th17 cells in GO patients, which are relevant to disease activity. We find that IL-17A has a synergistic promoting effect on TGF-b-driven fibrosis in CD90 + OFs, but reduces fat formation caused by 15-deoxy-D 12,14 -prostaglandin J 2 (15d-PGJ 2 (PGE 2 ) to support Th17 cell differentiation, which can be inhibited by the nonsteroidal anti-inflammatory drug (NSAID) indomethacin. Our findings provide evidence supporting the possible interactivity between pathogenic Th17 cells and OFs. Inhibition of this pathophysiological cell communication loop may be useful as adjunctive therapy to GO patients in the future.
Materials and Methods

Patients and samples
Patients with GO (n = 34) and healthy subjects (n = 36) were recruited from the Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine. Subjects who had a history of other autoimmune diseases, chronic inflammation, recent trauma, or active infection were excluded from the study cohort. Peripheral blood samples and orbital connective tissues were taken from each patient during orbital decompression surgery when they were in euthyroid function and had not received any corticosteroid medication or radiation for at least 3 months. Control peripheral blood samples and orbital connective tissues were collected from healthy subjects undergoing orbital surgery for blepharoplasty. Informed consent was obtained from each participant. All studies were approved by the Ethics Committee of Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, and were conducted according to the tenets of the Declaration of Helsinki. Complete clinical and demographic descriptions of all the participating subjects are outlined in Supplemental Table 1 .
Cell experiment scheme
Detailed descriptions of the OF culture, treatment and differentiation, human naive CD4 + T cell purification, Th17 cell differentiation, and OF-Th17 cell coculture protocols used in this study can be found in the Supplemental Materials.
Flow cytometry
Living peripheral blood mononuclear cells were identified with allophycocyanin (APC)-Cy7-Fixable Viability Dye (eBioscience) and were stained for surface markers [fluorescein isothiocyanate-CD3, Alexa Fluor 700-CD8, BV711-CC chemokine receptor (CCR)6, peridinin chlorophyll proteinCy5.5-CD45RO, or phycoerythrin (PE)-Cy7-CD44, all from BD Biosciences]. After fixation and permeabilization, cells were stained for intracellular cytokines and transcription factors [BV421-retinoic acid-related orphan receptor (ROR)gt, BD Biosciences; PE-IL-17A, APC-IFN-g, or PE-Cy7-IL-22, all from eBioscience]. For OF staining, cells were incubated with surface antibodies [fluorescein isothiocyanate-CD90, PE-Cy5-CD34, PE-CD106, APC-CD54, or BV421-CD40, all from BD Biosciences; peridinin chlorophyll protein-major histocompatibility complex class II (MHC II), R&D Systems]. All fluorescence-activated cell sorting data were analyzed using FlowJo software (Tree Star).
Immunohistochemistry and immunofluorescence staining
For immunohistochemistry examinations, primary antibodies include anti-MHC II, anti-CD40, anti-CD106, and anti-CD54 antibodies (all from Abcam). For immunofluorescence examinations, primary antibodies include anti-IL-17RA, anti-CD90, anti-a-smooth muscle actin (a-SMA), and anti-ADFP antibodies (all from Abcam).
Luminex and enzyme-linked immunosorbent assays
Cytokines in the culture supernatants were measured by fluorescent bead-based multiplex assay (eBioscience) according to the manufacturer's instructions. Data were analyzed using MultiExperiment Viewer software.
For PGE 2 detection, a specific PGE 2 Express enzyme immunoassay kit (Cayman Chemical) was used according to the manufacturer's instructions.
PathScan intracellular signaling assay
The assay was conducted with a PathScan intracellular signaling array kit (Cell Signaling Technology) according to the manufacturer's protocols. Images were visualized by chemiluminescence and results were analyzed with MultiExperiment Viewer software.
Western blotting assay
Primary antibodies include anti-CD106, anti-CD54, anti-CD40, anti-MHC II, anti-CD90, anti-fibronectin, anti-collagen I, anti-MMP-2, anti-TIMP-I, anti-a-SMA, anti-adiponectin, anti-perilipin A, anti-ADFP, anti-PGE 2 , and anti-b-tubulin antibodies (all from Abcam), anti-PPAR-g, anti-smad2/3, anti-psmad2/3, anti-c-Jun N-terminal kinase (JNK), anti-p-JNK, anti-c-Jun, anti-p-c-Jun, anti-GSK-3b, anti-p-GSK-3b, anti-p-CEBP/a, and anti-p-CEBP/b antibodies (all from Cell Signaling Technology), and anti-cyclooxygenase (COX)-2 antibody (Cayman Chemical). ImageJ software (National Institutes of Health) was used for semiquantitative analysis by densitometry, and b-tubulin was used as a loading control for normalization.
Proteomics and bioinformatics analysis
Briefly, the CD90 + and CD90 2 OFs were pretreated with 100 ng/mL IL-17A for 48 hours. Prepared protein samples were then processed with digestion, tandem mass tag labeling, high pH reverse phase separation, and low pH nano-highperformance liquid chromatography-tandem mass spectrometry analysis. After principal component and partial least square discriminant analysis, the results were further handled by hierarchical cluster, Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes analysis, respectively.
Statistical analysis
Comparison among groups was assessed by a two-tailed Student t test, analysis of variance, or the nonparametric Mann-Whitney U test, as appropriate. Analyses were performed with SPSS version 19.0 (SPSS Inc.), and a P value of ,0.05 was considered statistically significant.
Results
Increased generation of CD44
hi pathogenic Th17 cells is detected in GO patients Th17 cells were characterized by the transcription factor RORgt and CCR6 (7, 12 Fig. 1A-D) . Additionally, we studied the potential relationships between CAS and those of IL-17A + (r = 0.66; P , 0.0001), IFN-g + (r = 0.77; P , 0.0001), and IL-22 + (r = 0.71; P , 0.0001) Th17 cells, which showed a significant positive correlation between the proportion of pathogenic Th17 cells and CAS (Fig. 1E ). These results suggest that the number of pathogenic Th17 cells in GO patients might represent a hallmark of disease severity and activity. CD44 is one of the prominent activation markers for T lymphocytes (13) . The expression of CD44 was comparable in CD3 + CD8 2 RORgt + CCR6 + Th17 cells from the two study cohorts (Fig. 1F ), suggesting that Th17 cells were highly activated in both groups. However, we discovered that only the CD44 hi subset of CD3 + CD8 2 RORgt + CCR6 + Th17 cells produced high levels of IL-17A in GO patients whereas the CD44 lo subset cannot (Fig. 1G ).
GO orbital tissues express increased levels of costimulatory molecules and CD90
Our results demonstrated that costimulatory molecules such as CD40 and MHC II, CD106 and CD54 were highly expressed in the adipose and interstitial cells of GO orbital connective tissues compared with healthy controls ( Fig. 2A) . Increased protein levels of CD40, MHC II, CD106, and CD54 were also confirmed by Western blotting ( Fig. 2B and 2C) .
Moreover, GO orbital connective tissues expressed more CD90 molecules ( Fig. 2B and 2C ). Surgical explants of GO patients displayed hemorrhage with hard pearl-like nodules of different sizes, presenting fibrosis ( Fig. 2D ), conforming to our previous study (10) . The cultured five individual OF strains derived from GO orbits also exhibited elevated CD90 expression (Fig. 2D ), which is consistent with an earlier study from Khoo et al. (14) . We further confirmed that IL-17RA is expressed on both CD90 + and CD90 2 OFs (Fig. 2E ).
IL-17A facilitates TGF-b-induced fibrosis in CD90
+ OFs in a JNK-dependent manner Our data revealed that TGF-b could induce fibrotic change in CD90 + cells from both GO and healthy subjects, but not the CD90 2 cells (Supplemental Fig. 2A ). We next stimulated CD90 + OFs from GO orbits with TGF-b in the presence of 10 ng/mL or 100 ng/mL IL-17A for 24 and 48 hours. In CD90 + OFs, IL-17A could enhance the fibrotic course induced by TGF-b, because different ECM such as collagen I, fibronectin, MMP-2, and TIMP-I expressions were observed in the costimulation of IL-17A and TGF-b (Fig. 3A) . Moreover, a low dose of IL-17A (10 ng/mL) was sufficient to synergize with TGF-b to mediate orbital fibrosis (Fig. 3A) . Besides, IL-17A facilitated the differentiation of CD90 + OFs into myofibroblasts characterized by enhanced expression of a-SMA (Fig. 3A) , which was also confirmed by immunofluorescence staining (Fig. 3B) .
To further explore the potential mechanism of IL-17A on OFs, we measured the IL-17A-mediated intracellular signaling in both CD90 + and CD90 -OFs from GO patients. The PathScan array revealed distinguishing IL-17A postreceptor signal transduction in CD90 + OFs compared with CD90 2 OFs (Fig. 3C ). Even though mitogenactivated protein kinases and signal transducers and activators of transcription were activated in both groups (Fig. 3C) , JNK appeared to be phosphorylated only in CD90 + OFs (Fig. 3C ). To verify this phenomenon, we determined the dynamic changes of this specific signal transduction in response to the costimulation with TGF-b and IL-17A. In addition to the phosphorylated smad2/3 initiated by TGF-b, IL-17A promoted the phosphorylation of JNK and the downstream target c-Jun in CD90 + OFs (Fig. 3D) . Using the JNK blocking agent SP600125, we observed a reversed profibrogenic effect on IL-17A-treated CD90
+ OFs in cooperation with TGF-b (Fig. 3D) . Additionally, the protein mass spectrometry analysis of IL-17A-treated CD90 + OFs revealed that IL-17A
could promote the expression of many ECM-and fibrosis-related proteins such as CO6A3, CO1A1, CO1A2, CO3A1, FND3B, COCA1, CO5A1, CO2A1, PCOC1, SERPH, CRIP2, TGM2, ITA5, FBN1, LAMB1, and CD248. However, the expression of proteins involved in collagen catabolic process and ECM disassembly such as CATD, CPNS1, SEPR, and CATK was dramatically inhibited (Fig. 3E) . Meanwhile, IL-17A upregulated EGLN, SMAD4, and TGFI that could help to assist TGF-b signaling (Fig. 3E) . The levels of ROR2, SDCB1, HMGB1, and DAB2P were also observed to be upregulated, which are positive regulators of JNK cascade and JUN kinase activity (Fig. 3E) .
IL-17A attenuates 15d-PGJ 2 -triggered adipogenesis in CD90 2 OFs possibly through inhibiting CEBP/a activation We found that 15d-PGJ 2 promoted the adipogenic process in both GO and normal CD90
2 OFs (Supplemental Fig. 2B ). To investigate the role of IL-17A in the GO adipogenic process, we treated CD90 2 OFs from GO patients with 15d-PGJ 2 in the presence of 10 ng/mL or 100 ng/mL IL-17A for 6 and 8 days. The adipogenic differentiation of CD90 2 OFs had greatly abated with either a low or high dose of IL-17A treatment. Decreased expression levels of lipid droplet-associating proteins including perilipin A and adipocyte differentiation-related protein were observed during 15d-PGJ 2 -triggered adipogenesis in CD90 2 OFs in the presence of IL-17A (Fig. 4A) .
The downregulated expression of PPAR-g and adiponectin also demonstrated impaired adipocyte differentiation (Fig. 4A) . Moreover, our immunofluorescence results also confirmed the inhibition of adipogenesis by IL-17A in CD90 2 OFs (Fig. 4B ).
Because IL-17A did not activate JNK pathways in CD90
2 OFs (Fig. 3C) , we next examined the potential targets of IL-17A signaling in CD90 2 OFs. IL-17A
interfered with the phosphorylation of CEBP/a upon 15d-PGJ 2 stimulation (Fig. 4C) . The phosphorylation of GSK-3b and CEBP/b was also detected in IL-17A-treated CD90 2 OFs (Fig. 4C) . shown; data were combined from at least three independent experiments). *P , 0.05, **P , 0.01, ***P , 0.001; NC, normal controls. Unlike the CD90 + subsets, proteomics study showed that IL-17A regulated lipid metabolism in CD90
2 OFs (Fig. 4D) . IL-17A repressed VIGLN, LRP1, TENX, and PGH1 that are related to fatty acid biosynthetic process (Fig. 4D) , whereas those elevated proteins are mainly associated with fatty acid b-oxidation (THIK, ACBD5, ACOX2, ABCD1, and ECHP) and fatty acid degradation, catabolic, and efflux processes (ACSL1, ACSL4, ACSL5, PAG15, EST1, PLPL8, ABCA1, APOL2, and S27A4) (Fig. 4D) . Additionally, RFIP5 is a negative regulator of adiponectin secretion, and SODM prevents adipocyte differentiation (Fig. 4D) . Moreover, IL-17A inhibited HMGA1 expression, a PPAR binding protein (Fig. 4D ).
CD90 + and CD90
2 OFs directly induce Th17 cell differentiation via PGE 2 production To understand the interplay between OFs and Th17 cells, we performed OF-Th17 coculture experiments using five different GO OF strains and autologous T cells. Our data demonstrated that Th17 cells promoted inflammation in both CD90 + and CD90 2 OFs. Luminex assay revealed abundant proinflammatory cytokine expression, especially IL-6, IL-8, and MCP-1, in the OFTh17 coculture supernatants after 24 and 48 hours (Fig. 5A ). The expression of MIP-3, TNF-a, and GM-CSF was also upregulated in the supernatants (Fig. 5A ). Low levels of IL-1b and no IL-23 were detected in our coculture systems (Fig. 5A) . Intriguingly, we found that both CD90 + and CD90
2
OFs regulated naive T cell differentiation toward the Th17 phenotype, as increased secretion of IL-17A was detected in the supernatants after 24-and 48-hour cocultures compared with cultured Th17 cells alone (Fig. 5B) . The OF-Th17 cocultures were also highly enriched for other Th17 cytokine production such as IL-22 and IL-21, as well as IFN-g, but not IL-4 and IL-10 ( Fig. 5B) . Because OFs rarely produced IL-1b and IL-23 ( Fig. 5A) , we supposed that there would be other mechanisms supporting Th17 polarization. We found that both CD90 + and CD90 2 OFs, but not Th17 cells, expressed a high level of COX-2 and secreted an increased amount of PGE 2 in the coculture system (Fig. 5C ). NSAIDs target COX (15), and we therefore blocked the PGE 2 synthesis in OFs using indomethacin, a widely used NSAID, and observed decreased expression of COX-2 and PGE 2 ( Fig. 5C ) with a corresponding reduction of RORgt + IL-17A + T cells compared with Th17 cells from OF-Th17 cocultures without indomethacin treatment (Fig. 5D ).
Th17 cells upregulate costimulatory molecule expression in CD34
+ cell subsets from both CD90 + and CD90 2 OFs Costimulatory molecules were overexpressed in GO orbital tissues ( Fig. 2A and 2B 
Discussion
We previously reported that Th17 cells were involved in GO pathogenesis (10, 11) . In this study, we defined an augmented population of IFN-g-and IL- and IL-1b in several models of autoimmunity and human inflammatory diseases such as experimental autoimmune encephalomyelitis and T cell transfer-induced colitis (8, 9, 16) . In GO, we observed increased levels of IL-23 and IL-1b both in the serum and the orbits (10), which may initiate a proinflammatory signaling cascade that guides the Th17 cells toward a more pathogenic phenotype. Therefore, understanding the dichotomous nature of Th17 cells is of the utmost importance to recognize their immunopathogenesis in GO.
In our study only the CD44 hi Th17 subpopulation was capable of producing IL-17A, which might be interpreted as a better activation state of GO Th17 cells. As CD44 is a major receptor for hyaluronan, mediating T cell adhesion to OFs (17), the highly expressed CD44 on Th17 surface may serve as an important signal to recruit themselves into the orbits.
Th17-type immunity is profibrotic (18) , and IL-17A directly promotes a-SMA expression and ECM deposition, causing fibrosis, in many human diseases such as systemic sclerosis (19, 20) , liver fibrosis (21), and asthma (22) . Similarly, we found that the increased level of IL-17A in the orbits leads to fibrotic changes in GO (10) . In this study, we revealed that surgical explants from GO patients showed apparent fibrotic appearance and GO OF strains exhibited enhanced CD90 expression. Although fibrosis was common in the static phase, most of our patients have moderate to severe or very severe GO, whose orbital tissues also present fibrotic changes. This was in line with the study from Pawlowski et al. (23) that increased cytokines such as TGF-b may contribute to orbital fibrosis, especially in severe GO. Because the level of Th17 cells is in concert with the dynamic phase of GO, we may conjecture that excessive Th17-type immune responses in severe active patients are likely to cause orbital fibrosis in advance. Regression of the inflammatory process, yet still higher Th17 cell proportion, continues to exacerbate fibrosis in the late inactive phase of GO. However, some of our patients were previously treated with either steroids or radiotherapy, and all of the patients were in euthyroid function before orbital decompression. This could affect Th17 cell distribution in the blood and orbital tissue remodeling, interfering with the actual intrinsic relationship between For some experiments, indomethacin (20 mM) was added in the coculture systems. Data are presented as mean 6 SD combined from at least three independent experiments. *P , 0.05, **P , 0.01, ***P , 0.001; ns, nonsignificant.
Th17-type immunity and the natural course of GO. Further studies into the Th17 cell phenotype and orbital tissues at the onset of GO and observation of their dynamical changes are warranted.
In the presence of TGF-b, both GO and normal CD90 + OFs developed into myofibroblasts and produced ECM, whereas the CD90 2 OFs differentiated into lipid-bearing adipocytes after exposure to 15d-PGJ 2 .
OFs from Graves or normal orbits responded similarly to stress conditions such as PGE 2 (24) , IL-1b (25) , and quercetin (26), as previously reported. We think the in vitro culture for GO and normal OFs are basically under static situation and could be possibly returned to the same "baseline" state prior to each experiment with cytokine stimulation. The difference may lie in the in vivo inflammatory microenvironment where GO OFs are located. Our study unraveled that IL-17A collaboratively worked with TGF-b on the fibrotic process of CD90 + OFs, which helps to expound the codependent roles for IL-17A and TGF-b in the development of GO fibrosis and other autoimmune diseases (18) . The activation of JNK-driven transcription is independent from TGF-b-mediated smad phosphorylation in CD90 + OFs. Proteomics study corroborated the previous conclusions, showing that IL-17A not only induced fibrosis by promoting ECM synthesis, but also was propitious to the action of TGF-b in CD90 + OFs.
We discovered that IL-17A had an antiadipogenic effect on 15d-PGJ 2 -treated CD90
2 OFs, which was in line with previous studies on other cell types (27) (28) (29) (30) . IL-17A phosphorylated GSK3b, an inhibited state of this kinase (31) , and impeded 15d-PGJ 2 -induced activation of CEBP/a in CD90 2 OFs.
GSK-3b phosphorylates CEBP/a and is required for adipocyte development (31) . The suppressive effect of IL-17A on adipogenesis in CD90 2 OFs may be attributed to the dephosphorylation of CEBP/a through the inactivation of GSK-3b. The mechanisms for the inhibition of lipogenesis by IL-17A are complicated and multiform in different cell lines (27) (28) (29) (30) Inhibition of PGE 2 production using indomethacin restrained the supporting role of OFs in Th17 cell differentiation. Many studies have reported the role of PGE 2 on Th17 differentiation (32) (33) (34) (35) (36) . Although IL-23 is important for a PGE 2 -initiated Th17 phenotype, these studies did not conduct the direct fibroblast-Th17 cocultures (32) (33) (34) (35) . In our study, the supporting effect of PGE 2 was IL-23-independent, as IL-23 was undetectable in the supernatants. Our data are consistent with previous findings of 2 OFs by impeding the phosphorylation of CEBP/a resulting from 15d-PGJ 2 stimulation. In turn, activated OFs express more CD40 and MHC II that help to further stimulate Th17 cells through CD40L-CD40 and TCR-MHC II combinations. OFs also produce excessive PGE 2 to trigger Th17 differentiation and function, which amplifies the autoimmune reactions in the orbits.
synovial fibroblasts from rheumatoid arthritis observed by Paulissen et al. (36) . Despite the synergistic action of PGE 2 and IL-23 on Th17 differentiation, our studies and those by Paulissen's group help to draw out the intensive induction of Th17 lineage by fibroblasts via PGE 2 in the context of GO and other autoimmune diseases.
Alternatively, Th17 cells promoted various proinflammatory cytokine production in CD90 + and CD90
2
OFs, leading to orbital inflammation. In a previous study on total T cell-OF cocultures, the costimulatory molecule MHC II was observed to be elevated on OFs (37 (37) and thus further stimulation of Th17 cells. So far, there is no ideal medical management of GO. The complexity of GO pathogenesis may increase the probability of developing a novel therapeutic regimen. Blocking B cells by rituximab (38) and reducing oxidative stress with selenium supplementation (39, 40) have shown encouraging results. Our study suggests the involvement of pathogenic Th17 cells in GO. The interplay between Th17 cells and OFs promotes orbital inflammation and fibrosis, and it strengthens Th17-OF communication via augmented costimulatory molecules (Fig. 6) . Abating OF-driven Th17 cell programming with indomethacin and other kinds of COX inhibitors may provide better therapeutic strategies for GO and other inflammatory autoimmune diseases.
